- Home
- BTAI vs OTLK Comparison
BTAI vs OTLK Comparison
Compare BTAI & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BTAI
- OTLK
- Stock Information
- Founded
- BTAI 2017
- OTLK 2010
- Country
- BTAI United States
- OTLK United States
- Employees
- BTAI N/A
- OTLK N/A
- Industry
- BTAI Biotechnology: Pharmaceutical Preparations
- OTLK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BTAI Health Care
- OTLK Health Care
- Exchange
- BTAI Nasdaq
- OTLK Nasdaq
- Market Cap
- BTAI 48.3M
- OTLK 42.8M
- IPO Year
- BTAI 2018
- OTLK 2016
- Fundamental
- Price
- BTAI $2.05
- OTLK $1.26
- Analyst Decision
- BTAI Buy
- OTLK Buy
- Analyst Count
- BTAI 5
- OTLK 5
- Target Price
- BTAI $32.80
- OTLK $5.25
- AVG Volume (30 Days)
- BTAI 987.3K
- OTLK 1.6M
- Earning Date
- BTAI 11-12-2025
- OTLK 08-14-2025
- Dividend Yield
- BTAI N/A
- OTLK N/A
- EPS Growth
- BTAI N/A
- OTLK N/A
- EPS
- BTAI N/A
- OTLK N/A
- Revenue
- BTAI $868,000.00
- OTLK $1,505,322.00
- Revenue This Year
- BTAI N/A
- OTLK N/A
- Revenue Next Year
- BTAI $614.78
- OTLK $342.80
- P/E Ratio
- BTAI N/A
- OTLK N/A
- Revenue Growth
- BTAI N/A
- OTLK N/A
- 52 Week Low
- BTAI $1.17
- OTLK $0.79
- 52 Week High
- BTAI $12.16
- OTLK $6.98
- Technical
- Relative Strength Index (RSI)
- BTAI 34.65
- OTLK 48.12
- Support Level
- BTAI $2.14
- OTLK $1.28
- Resistance Level
- BTAI $2.46
- OTLK $1.48
- Average True Range (ATR)
- BTAI 0.16
- OTLK 0.10
- MACD
- BTAI -0.00
- OTLK -0.01
- Stochastic Oscillator
- BTAI 9.03
- OTLK 9.68
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.